Opus Genetics ($IRD) Insider Trading & Smart Money Activity
Opus Genetics, Inc. ($IRD) has 1 insider trade and 3 analyst ratings on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($2.76M), net -$2.76M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$2.76M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 0
- Analyst ratings on file
- 3
IRD insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 1 · $2.76M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All IRD insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Foundation Fighting Blindness Retinal Degeneration FundDirector | Sell (Open-market sale) | 556K sh | $2.76M | -8.9% | — | |||||
| Analyst | Chardan Capital | Reiterates to buy | PT $13 | -8.6% | -25.1% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $8 | -8.6% | -19.5% | Read | |||||
| Analyst | HC Wainwright | Reiterates to buy | PT $8 | -8.6% | -19.5% | Read |
1W / 1M / 6M = how IRD moved from the trade or filing date.
Insider trading in IRD: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | Director | 1 | -$2.76M | Sep 30, 2026 |
Analyst ratings on IRD
Frequently asked questions
Are IRD insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $2.76M, a net -$2.76M.
What is the latest insider trade in IRD?
Foundation Fighting Blindness Retinal Degeneration Fund, Director filed a sell (open-market sale) of 556K sh worth $2.76M on Sep 30, 2026.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.